These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30575098)

  • 1. Bortezomib ocular toxicities: Outcomes with ketotifen.
    Dennis M; Maoz A; Hughes D; Sanchorawala V; Sloan JM; Sarosiek S
    Am J Hematol; 2019 Mar; 94(3):E80-E82. PubMed ID: 30575098
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate.
    Aguilar AJ
    Acta Ophthalmol Scand Suppl; 2000; (230):52-5. PubMed ID: 11057352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patients.
    Bird S; Pawlyn C; Nallamilli S; Sriskandarajah P; Kaiser M; Yong K; Popat R; Rabin N; Boyd K
    Br J Haematol; 2020 Dec; 191(5):927-930. PubMed ID: 33460042
    [No Abstract]   [Full Text] [Related]  

  • 5. Chalazia associated with bortezomib therapy.
    Laaribi N; Abdellaoui T; Abaloun Y; Fiqhi A; Rabii H; Haidouri S; Mouzari Y; El Asri F; Reda K; Oubaaz A
    J Fr Ophtalmol; 2018 Oct; 41(8):e381-e382. PubMed ID: 30172381
    [No Abstract]   [Full Text] [Related]  

  • 6. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%.
    Artal MN; Luna JD; Discepola M
    Acta Ophthalmol Scand Suppl; 2000; (230):64-5. PubMed ID: 11057355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model.
    D'Arienzo PA; Leonardi A; Bensch G
    Clin Ther; 2002 Mar; 24(3):409-16. PubMed ID: 11952024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat.
    Schoch C
    Ocul Immunol Inflamm; 2005 Feb; 13(1):39-44. PubMed ID: 15804768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
    Berdy GJ; Spangler DL; Bensch G; Berdy SS; Brusatti RC
    Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.
    Gatt ME; Hardan I; Chubar E; Suriu C; Tadmor T; Shevetz O; Patachenco P; Dally N; Yeganeh S; Ballan-Haj M; Cohen Y; Trestman S; Muchtar E; Magen H; Jakubinsky J; Avivi I;
    Eur J Haematol; 2016 Feb; 96(2):136-43. PubMed ID: 25827161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity associated with bortezomib: A single-center experience.
    Gurram MK; Pulivarthi S; Ehresmann K; Mathew J
    J Cancer Res Ther; 2017; 13(6):961-963. PubMed ID: 29237959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study.
    Torkildsen GL; Ousler GW; Gomes P
    Clin Ther; 2008 Jul; 30(7):1264-71. PubMed ID: 18691985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
    Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
    Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketotifen fumarate treatment of superior limbic keratoconjunctivitis.
    Udell IJ; Guidera AC; Madani-Becker J
    Cornea; 2002 Nov; 21(8):778-80. PubMed ID: 12410035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib-containing regimens are effective in multiple myeloma--results of a non-interventional phase IV study.
    Knauf W; Tapprich C; Schlag R; Schütz S; Alkemper B; Gaede B; Reschke D; Schmits R; Schwarzer A
    Oncol Res Treat; 2015; 38(4):167-73. PubMed ID: 25877940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.
    Mangiacavalli S; Pochintesta L; Ravelli E; Baldini L; Ferretti VV; La Targia ML; Farina L; Cocito F; Cairoli R; Montefusco V; Corso A
    Leuk Lymphoma; 2015 Jun; 56(6):1901-2. PubMed ID: 25347423
    [No Abstract]   [Full Text] [Related]  

  • 17. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study.
    Grammatico S; Bringhen S; Vozella F; Siniscalchi A; Boccadoro M; Petrucci MT
    Leuk Lymphoma; 2017 Nov; 58(11):2738-2740. PubMed ID: 28402163
    [No Abstract]   [Full Text] [Related]  

  • 19. Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study.
    Terpos E; Gobbi M; Potamianou A; Lahaye M; Couturier C; Cavo M
    Eur J Haematol; 2018 Jan; 100(1):10-19. PubMed ID: 28801967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).
    Waldschmidt JM; Keller A; Ihorst G; Grishina O; Müller S; Wider D; Frey AV; King K; Simon R; May A; Tassone P; Duyster J; Jung M; Raje N; Wäsch R; Engelhardt M
    Haematologica; 2018 Oct; 103(10):e473-e479. PubMed ID: 29674494
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.